IGF-1, instead, enhances insulin metabolic and anabolic action, and lower IGF-1 levels have been shown to associate with impaired glucose tolerance, insulin resistance and metabolic syndrome, and to predict T2DM onset [15, 35–37]. This evidence concerns the gene INS and metabolic syndrome.